Innate Pharma SA
PAR:IPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innate Pharma SA
PAR:IPH
|
FR |
|
Nutralife Biosciences Inc
OTC:NLBS
|
US |
|
B
|
BNC Korea Co Ltd
KOSDAQ:256840
|
KR |
|
T
|
Taokaenoi Food & Marketing PCL
SET:TKN
|
TH |
|
B
|
Best SA
WSE:BST
|
PL |
|
Ducon Infratechnologies Ltd
NSE:DUCON
|
IN |
|
V
|
Vext Science Inc
CNSX:VEXT
|
CA |
|
Danaos Corp
NYSE:DAC
|
GR |
|
G
|
Green Resource Co Ltd(Incheon)
KOSDAQ:402490
|
KR |
|
Canstar Resources Inc
XTSX:ROX
|
CA |
Bankruptcy Probability
Innate Pharma SA's probability of bankruptcy is hidden . The solvency score is hidden .
We take all the information about a company's solvency (such as how easily a company can pay interest on its outstanding debt, how much cash it has, the amount of debt, and more) and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Innate Pharma SA Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FR |
|
Innate Pharma SA
PAR:IPH
|
110.1m EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
374.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Innate Pharma SA's probability of bankruptcy is hidden .
The probability of bankruptcy is estimated using credit risk models that assess its financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Innate Pharma SA has total debt of 13.8m EUR. This includes both short-term (0 EUR) and long-term (13.8m EUR) debt.
You can find a full breakdown on its Balance Sheet.
